DEPLOYDatabase

Company

Stryker

Stryker Corporation (NYSE: SYK) is one of the world's largest medical technology companies, headquartered in Kalamazoo, Michigan, with $25B in 2025 revenue and…

Track Stryker
Founded
1941
HQ
Kalamazoo, MI, USA
Status
public (NYSE: SYK)

Models

2

Overview

Stryker Corporation (NYSE: SYK) is one of the world's largest medical technology companies, headquartered in Kalamazoo, Michigan, with $25B in 2025 revenue and approximately 56,000 employees. The company's Mako SmartRobotics platform is the leading robotic orthopedic surgery system, with record Mako installations in 2024 for hip and knee replacements, and the next-generation Mako showcased at AAOS 2025 including the new Mako Shoulder application.

Verified record

Verified deployments
None on file
Active incidents
9 incidents on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

Mako SmartRobotics robotic-arm orthopedic system (knee/hip/spine/shoulder).

Boundary

AI-augmented surgeon-controlled assistance, NOT autonomous.

Stock ticker

NYSE: SYK

Market position

Mako SmartRobotics is the market-leading robotic-arm system for orthopedic joint replacement

Acquisition

Acquired MAKO Surgical in 2013 for ~$1.65B

CEO

Kevin Lobo (Chair & CEO)

Revenue

$25B (2025)

Stock

NYSE: SYK

Employees

approximately 56,000

Robotics platform

Mako SmartRobotics (hip, knee, shoulder)

Mako platform

Hip, Knee, Spine, Shoulder + Mako RPS handheld (2026)

Mako price

$800,000-$1,400,000 (Mako 4 next-gen)

Data & sources

Company filings

1

Press releases

2

3 sources backing this record.View all →

Models (2)

View all models →

Current platform

Stryker Mako SmartRobotics

Robotic arm for knee and hip replacement surgery. AccuStop haptic feedback and patient-specific planning.

surgicalView model →

Current platform

Mako

Mako (marketed as Mako SmartRobotics) is Stryker's surgeon-guided robotic-arm system for orthopedic joint replacement, recorded in the surgical form factor as the large-footprint, CT-based commercial-market-leader archetype of the orthopedic sub-cohort. It pairs CT-based three-dimensional pre-operative planning with intra-operative haptic boundary control, branded AccuStop, that physically constrains the saw or burr to the planned resection zone, and real-time optical bone tracking that keeps that boundary registered to the patient; the surgeon holds and guides the arm and makes every cut, so the system is AI-augmented surgeon-controlled assistance and not autonomous surgery, the same assistive class as Intuitive's da Vinci. Made by Stryker, listed on the New York Stock Exchange as SYK, founded in 1941 by Dr. Homer H. Stryker, incorporated in Michigan in 1946 and headquartered in Portage, Michigan, the platform entered Stryker through its roughly 1.65 billion dollar acquisition of MAKO Surgical at thirty dollars per share, announced September 25, 2013 and closed December 17, 2013, when MAKO's product was the RIO system cleared for partial knee and total hip. Its FDA-cleared scope has since broadened to partial and total knee, cementless total knee, total hip, a hip-revision feature, the Mako Spine System for non-cervical pedicle-screw placement cleared under 510(k) K241517 in May 2024, and the Mako Shoulder application for reverse shoulder arthroplasty cleared under 510(k) K242373 in November 2024. Per Stryker's FY2024 10-K the system is sold in more than forty-five countries with more than one million robotic Mako Total Knees and 1.5 million total Mako procedures performed cumulatively, and Stryker describes itself as one of four leading global competitors rather than asserting a specific market share; no installed-base system count appears in the 10-K, so any thousands-of-systems or market-share figure is aggregator-sourced and is not asserted here.

surgicalView model →

Stryker on the deployment map

Where Stryker's robots are verified operating. Explore the deployment map by place and type.

Explainers

Plain-language answers to the questions people ask about Stryker, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is Stryker Mako?

    Stryker Mako is a large-footprint CT-based robotic-arm-assisted orthopedic surgical system from Stryker (NYSE: SYK; HQ Portage, MI per Agent A correction, NOT Kalamazoo). Mako was acquired in 2013 via Stryker's $1.65B acquisition of MAKO Surgical. Per Agent A orthopedic ingest: FDA-cleared multi-procedure (partial + total + cementless knee + hip + hip-revision + spine via K241517 + shoulder via K242373); CT-based pre-op planning + robotic-arm-assisted intra-op execution. AI-augmented surgeon-controlled assistance (NOT autonomous; software plans/tracks/bounds, surgeon makes the cuts); same assistive class as Intuitive da Vinci, framed honestly + consistently across the cohort. Editorial throughline: large-footprint orthopedic market-leader archetype within the surgical cluster's orthopedic sub-cohort; multi-procedure platform spanning knee + hip + spine + shoulder; SEC-disclosed parent-company verification depth.

  • Why does DEPLOY surface Stryker as headquartered in Portage, MI, not Kalamazoo?

    Common framing across press coverage + aggregator listings + secondary references identifies [Stryker Corporation](https://registry.deploy.report/companies/stryker) as headquartered in Kalamazoo, Michigan. Per Agent A primary-source verification against SEC 10-K filings, Stryker is headquartered in **Portage, Michigan**, not Kalamazoo. Small fact. Foundational at the framework-discipline layer. The Stryker headquarters correction is the canonical worked example of small-fact discipline cuts uniformly: DEPLOY reads single-city location identification at the same primary-source verification depth as $5.6B-vs-$11B valuation corrections + Doug-Unis-CMO-vs-CEO leadership corrections + corporate-state-transition multi-fact precision. The framework operates at per-claim depth; per-claim depth doesn't scale with company size or fact magnitude. This piece documents the catch as framework-in-action worked example demonstrating small-fact discipline + primary-source verification at single-city location identification depth + uniform application of the framework across granularity.

  • How does DEPLOY think about robot insurance?

    DEPLOY thinks about robot insurance as a four-dimension actuarial framework operating recursively across the verified-vs-claimed throughline: deployment-incident-recall actuarial depth (61 verified incidents at primary-source-anchored severity + root-cause + regulatory-action depth; exposure denominators absent at most deployments); manufacturer financial-state / counterparty risk (114 investors + 58 funding rounds + 29 acquisitions verified; financial state vs relationship state distinction); supply-chain component failure analysis (absent as structured substrate; bounded to safety-critical components when authored); regulatory clearance per jurisdiction (34 verified filings lopsided 94% US-FDA-only; jurisdictional completeness is the load-bearing gating layer for insurability per region). The discipline that distinguishes DEPLOY's framework from the broader insurance-discourse cohort: honest 'insurability unknown for this region / no exposure data' is more valuable than a fabricated rate. Cap-flag-as-trust-signal operates recursively on actuarial framing.

  • How does DEPLOY track acquisition history state?

    DEPLOY tracks acquisition history state as a five-structure taxonomy operating at relationship-graph granularity per Agent A's Arc D substrate (29 acquisitions + 20 FK-acquirer + 9 external + 7 acquired-assets typed). The structure taxonomy: full_acquisition (acquirer absorbs target entirely; target ceases as independent entity) → asset_purchase (specific assets transfer; target may continue) → acqui_hire (team transfers; assets minimal) → license_and_hire (Amazon × Covariant canonical: RFM models licensed + team transitions; Covariant remains standalone under Stinson; ~25% staff transition documented) → spac_merger (de-SPAC pattern; Sarcos → Palladyne canonical example). The four-state valuation_basis discipline: exact (SEC-disclosed or court-record) versus reported (press-release; not SEC-verifiable) versus undisclosed (transaction confirmed but valuation not disclosed) versus contingent (ZB × Monogram CVR canonical: structured contingent payment with earnout). The canonical lesson banked at validator-discipline depth: exact name match only, never alias-contains, in M&A graphs (6 acquisitions reverted from alias-contains reconciliation bug). Cap-flag-as-trust-signal operates recursively on acquisition framing.

  • How does DEPLOY track manufacturer counterparty risk at financial-state-axis granularity?

    DEPLOY tracks Phase 3 Dim 2 manufacturer counterparty risk substrate at primary-source-anchored verification depth per Agent A's mfs=7 manufacturer_financial_states baseline backfill: Intuitive Surgical FY2024 $8.35B (sec_10k; mature; counterparty=low) + Stryker nine-month 2024 $16.16B (sec_10q; mature; counterparty=low; SEC-verified-figure-with-narrower-precision-cap-flag CANONICAL worked example) + Zimmer Biomet FY2024 $7.68B (sec_8k; mature; counterparty=low) + Boston Dynamics private_reported NULL revenue (mature; counterparty=low via Hyundai ~80% parent-backing CANONICAL worked example for counterparty-risk-by-parent-backing classification) + Apptronik private_reported NULL (growth; counterparty=moderate; recent $350M Series A Feb 2025) + Figure AI private_reported NULL (growth; counterparty=moderate; ~$1B Series C 2025 at ~$39B reported valuation) + 1X Technologies private_reported NULL (growth; counterparty=moderate; 2024 Series B ~$100M EQT-led + subsequent 2025 round). Cap-flag-as-trust-signal recursive at three substantive layers: SEC-verified-figure-with-narrower-precision-cap-flag pattern (Stryker Q3 nine-month $16,159M used instead of unverified FY extrapolation; verified-vs-claimed at sub-fiscal-period granularity) + honest-absence on private-financials USD fields (Apptronik + Figure + 1X all NULL revenue at honest-absence cap-flag pending primary-source disclosure) + cash_runway_basis NULL when cash_runway_months NULL across the board (validator-aware discipline; cash_runway_months not publicly-disclosed for any of these makers; cash_runway_basis stays NULL preserving validator integrity). Counterparty-risk-by-parent-backing classification discipline as canonical: Boston Dynamics counterparty=low via Hyundai ~80% subsidiary parent-backing vs Apptronik/Figure/1X counterparty=moderate as growth-stage privates without parent-backing.

Current leadership (5)

Board (1)

Former / Previously (3)

  • Rony Abovitz Founder & CTO, MAKO Surgical (acquired by Stryker 2013)secondary-verified
  • Anthony Fernando VP, Innovation & Technologysecondary-verified
  • Maurice Ferre President & CEO, MAKO Surgical (acquired by Stryker 2013)secondary-verified

Safety record

6 recalls and 3 incidents on record (6 serious, 2 moderate). Most recent: Apr 2025.

serious
6
moderate
2
Severity not classified
1
recall
6
malfunction
2
injury
1

Most recent: Apr 2025

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Stryker (9)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Recent coverage

Stryker in third-party press

Stryker expands Mako robotics portfolio with full market release of Mako RPS

Jul 16, 2026

Stryker fully launches Mako robotic power system for knee surgery in US

Jul 16, 2026

Stryker expands Mako robotics portfolio with full market release of Mako RPS

Jul 16, 2026

Peer companies